Articles tagged with Personalized Medicine
Researchers developed a comprehensive tool to explore disease development patterns, identifying main highways of disease progression. The Danish Disease Trajectory Browser analyzes 25 years of public health data to discover frequent disease trajectories.
Scientists have developed biocompatible TeSex nano-alloys that eliminate toxicity and enhance theranostic performances for precision medicine. The nano-alloys enable high-efficacy photothermal therapy under multimodal imaging guidance.
The human genome's complexity hinders personalized medicine by having an immense ability to change and cope with issues, context matters in our genome. Researchers conclude that precision medicine is crucial but must consider the full genomic blueprint including 'unnecessary' elements.
CURATE.AI is an AI-derived mechanism-independent technology platform that profiles individual patients based on their data and recommends optimal drug doses. This approach aims to improve treatment efficacy while reducing toxicity levels and addressing the challenges of personalized dosing.
Researchers have developed a method to monitor and predict the progression of atrial fibrillation using cardiac electrical signals from implantable devices. This technology enables personalized treatment timing, optimizing medical intervention for individual patients.
This special issue focuses on advancements in technologies that enable predictive, preventative, and personalized medicine. The articles cover various topics such as biomicrofluidic systems, purification and enrichment of extracellular vesicles, and electrochemical sensors.
A study by San Diego State University researcher Rob Edwards found a country-specific biomarker for the crAssphage virus in humans, which rapidly changes with travel. The research analyzed over 32,000 sequences from 65 countries and revealed the phage's global distribution.
New research highlights the importance of diverse genetic data in understanding complex traits and diseases. By studying a large number of groups together, scientists have discovered dozens of discoveries that would not have been possible in single-population studies.
The EU-STANDS4PM forum aims to develop standardized transnational frameworks for data integration and in silico modeling in personalized medicine. This will facilitate the use of life science data in clinical research and accelerate growth of the European data-driven economy.
A review paper highlights the transformative potential of precision and personalized medicine for cancer treatment. The traditional approach focuses on general treatments, while PPM allows for individualized treatments tailored to specific tissues and gene mutations.
The Quadratic Phenotypic Optimization Platform (QPOP) uses AI to analyze small datasets and design optimal drug combinations based on real experimental data. This approach can optimize and personalize combination therapy for individual patients with complex diseases, such as multiple myeloma.
A KAIST research team has developed a flexible drug delivery device with controlled release, blurring the path toward theragnosis. The device boasts fewer side effects and uniform therapeutic results compared to oral ingestion, making it suitable for smart contact lenses and brain disease treatments.
The research aims to assess the cost-effectiveness of LHSC's personalized medicine program, which uses pharmacogenomics to predict patient responses to medications. The study will compare patient outcomes with those in the province using provincial health care data.
Researchers have developed a novel omics tool to explore the interaction between genetics, environment, and disease. By integrating large datasets from the BXD mouse population, scientists can identify gene-phenotype associations and make personalized treatment predictions.
Computational biologists discover that protein variations have a significant impact on cell functions, even in healthy individuals. The study's findings could lead to advances in personalized medicine and better understanding of individual responses to environmental influences.
A new study found that generous health insurance plans with low deductibles and copays can lead to unnecessary treatments for chronically ill patients. The study suggests that personalized medicine interventions, providing more information about treatment effectiveness, can reduce healthcare costs and improve patient outcomes.
Researchers have developed a new approach to create integration-free, Myc- and Lin28-free human induced pluripotent stem cells. This breakthrough method reduces the neoplastic risk associated with IPSC generation, enabling their utility in regenerative medicine and personalized medicine.
Personalized Medicine in Psychiatry aims to increase treatment efficacy and reduce adverse effects by considering individual patient characteristics. The journal will publish research on endophenotypes, pharmacologic approaches, and education, with the goal of identifying predictors of response and tailoring treatments.
Seventy percent of patients who kept their gallbladders despite experiencing biliary pancreatitis had no recurrence four years later. A large database analysis found that many patients who did not undergo surgery within 30 days still had no recurrences over a four-year follow-up period.
Researchers at Boston University School of Medicine have developed a novel approach to generate airway cells from stem cells using the Wnt signaling pathway. These cells can be grown into three-dimensional spheres and used to study lung diseases such as cystic fibrosis.
Researchers have discovered significant differences in cells derived from dura mater and skin samples across the lifespan, highlighting the importance of considering the cell's original location and donor age. These findings necessitate further exploration into epigenetic patterns in stem cells used for new tissue and organ generation.
A global research team has identified 52 genetic variants associated with age-related macular degeneration (AMD), a disease affecting 150 million people worldwide. The discovery may lead to personalized medicine approaches and new treatments for this debilitating condition.
More than 120 US engineering schools pledged to graduate 20 'Grand Challenge Engineers' per year, trained through special programs with a focus on hands-on research, global perspectives, and service-learning. The goal is to train over 20,000 engineers to address societal challenges.
Researchers at U of MD will implement genomic screening in various healthcare settings to detect monogenic diabetes, tailor treatments, and identify at-risk family members. The goal is to enhance diagnosis and treatment for individuals with genetic forms of diabetes.
Researchers have made progress in designing therapies for patients with specific genetic traits, particularly in cancer treatment. However, the field still faces significant hurdles, including a need to incorporate individuals' health histories and environmental factors into personalized medicine.
The Mount Sinai Hospital is launching the first-ever genetic testing program in primary care settings to identify genetic risk for kidney disease in patients with hypertension. This $3.7 million grant will provide genomic information to individualize treatment, testing, and monitoring, with a focus on African Americans who are four to ...
Research by Northwestern Medicine cardiologist Jeffrey Goldberger combines evidence-based guidelines with tailored treatment for patients, reducing over-treatment and under-treatment. By analyzing clinical data and individual characteristics, physicians can make more precise decisions, leading to better patient care.
A recent study found that vaginal microbes change in some healthy women over short periods, while remaining stable in others. These changes can impact a woman's susceptibility to infections and diseases. Researchers hope this research will lead to personalized medicine for women.
The Canadian Institutes of Health Research will lead a landmark research competition to develop personalized treatments for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. The investment aims to transform the delivery of healthcare through predictive, preventive, and precision care.
Researchers propose using personalized medicine to identify individuals at highest risk for developing type 2 diabetes, allowing for targeted prevention efforts. Current methods are inefficient, but new biomarkers and approaches hold promise for preventing and controlling the disease.
A new study found that more than 85% of US states have inadequate genetics standards for preparing high school students for personalized medicine. The study, published by the American Society of Human Genetics, rates only seven states as 'adequate' in genetic literacy.
The American Chemical Society honors Keith H. Gibson, Andrew J. Barker, and George L. Trainor for their contributions to personalized medicine and genetic sequencing. The trio developed a new drug that helped pioneer the era of 'personalized medicine' for cancer patients.
Despite genomics' promise in treating cancer and cardiovascular disease, personalized medicine's complexities limit tailored interventions. The authors advocate for a more holistic approach focusing on the person as a whole, rather than abstract scientific manipulations.
The Research Institute of the McGill University Health Centre (RI-MUHC) has been awarded a $1.4M grant to develop Personalized Medicine for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). The project aims to identify new biomarkers and disease predictors to improve diagnosis and treatment options.
A recent study published in PLOS ONE found that ancestral genetic heritage is not fixed at the individual level for African-American and Hispanic patients, but rather varies widely within each group. This research challenges traditional ethnic labels and highlights the importance of considering individual genotypes in personalized medi...
This special issue of Perspectives on Psychological Science investigates the potential of genetics research, personalized medicine, and behavioral intervention to improve patient care. The articles examine the intersection of behavior and genetics, with a focus on tailoring treatments to individual genetic characteristics.
A series of essays examines the challenges in determining effective treatments, benefits and drawbacks for patients, as well as consumers' right to their genetic information. The articles discuss controversies surrounding direct-to-consumer tests, genetically customized drug treatments and biospecimen use.
This special edition of The Hastings Center Report examines the promise and pitfalls of personalized medicine, from direct-to-consumer genetic testing to hospice care. Key findings include the need for thousands of human biospecimens for genetic studies, as well as debates over individual mandates in healthcare reform.
Experts in pathology are advocating for a comprehensive training program to integrate genomics and personalized medicine into daily practices. The proposed curriculum would cover laboratory medicine, genetic counseling, and health information technology, enabling pathologists to serve as primary consultants for physicians and patients.
A model predicting warfarin doses based on genetic information and clinical factors shows improved results, particularly for patients at high risk of bleeding or clotting. The study suggests personalized medicine holds promise in optimizing medication treatment.
Canada has a unique opportunity to become an international leader in personalized medicine, driven by advancements in human genome sequencing and genetic research. The country can capitalize on its strengths to provide a model for other nations.
A $12.5 million grant from Charles Bronfman will establish the Charles Bronfman Institute for Personalized Medicine, transforming medical practice with genomics-based strategies for disease detection and treatment. The gift will seed a $30 million initiative to advance personalized medicine at Mount Sinai.
As pharmacogenomics adoption advances, physicians are at risk of lawsuits for not recommending genetic tests before prescribing drugs that may harm patients with genetic vulnerabilities. Experts predict an increase in liability risks, citing scientific uncertainty, social concerns, and economic costs as hurdles.
Mount Sinai Journal of Medicine will transition to Wiley, focusing on translational and personalized medicine, featuring articles on clinical care, bio-medical research, and patient outcomes. The journal's redesign aims to bridge the gap between scientific discovery and clinical application.
A new system, Genomic Messaging System (GMS), has been developed to store and transmit whole sequences of patient DNA in a compressed form while maintaining privacy. This technology could enable doctors to prescribe tailored treatments based on unique genetic variations.